Compare · BNTX vs SOPH
BNTX vs SOPH
Side-by-side comparison of BioNTech SE (BNTX) and SOPHiA GENETICS SA (SOPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and SOPH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $28.34B, about 39.4x SOPH ($719.3M).
- Over the past year, BNTX is up 7.2% and SOPH is up 145.1% - SOPH leads by 137.8 points.
- SOPH has been more active in the news (13 items in the past 4 weeks vs 7 for BNTX).
- BNTX has more recent analyst coverage (25 ratings vs 14 for SOPH).
- Company
- BioNTech SE
- SOPHiA GENETICS SA
- Price
- $112.84-3.19%
- $8.43-2.54%
- Market cap
- $28.34B
- $719.3M
- 1M return
- +26.33%
- +46.86%
- 1Y return
- +7.24%
- +145.06%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 7
- 13
- Recent ratings
- 25
- 14
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
SOPHiA GENETICS SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
- SEC Form 6-K filed by BioNTech SE
- BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
- Amendment: SEC Form 20-F/A filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
Latest SOPH
- Chief People Officer Valente Manuela exercised 10,000 units of Ordinary Shares at a strike of $3.20 and sold $79,439 worth of Ordinary Shares (10,000 units at $7.94) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu sold $163,482 worth of Ordinary Shares (20,000 units at $8.17) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,887 units (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu sold $30,076 worth of Ordinary Shares (4,000 units at $7.52) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 586,887 units (SEC Form 4)
- Chief Medical Officer Menu Philippe sold $37,580 worth of Ordinary Shares (5,000 units at $7.52) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 218,387 units (SEC Form 4)
- Executive Chairman Camblong Jurgi sold $209,209 worth of Ordinary Shares (28,500 units at $7.34) as part of a pre-agreed trading plan, decreasing direct ownership by 0.82% to 3,444,322 units (SEC Form 4)
- Chief Technology Officer Verma Abhimanyu sold $38,000 worth of Ordinary Shares (5,000 units at $7.60) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 182,171 units (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu exercised 10,000 units of Ordinary Shares at a strike of $3.28 and sold $144,924 worth of Ordinary Shares (20,000 units at $7.25) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 590,887 units (SEC Form 4)
- Executive Chairman Camblong Jurgi sold $138,412 worth of Ordinary Shares (20,000 units at $6.92) as part of a pre-agreed trading plan, decreasing direct ownership by 0.57% to 3,472,822 units (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu sold $69,168 worth of Ordinary Shares (10,000 units at $6.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 600,887 units (SEC Form 4)
- Chief Technology Officer Verma Abhimanyu sold $34,772 worth of Ordinary Shares (5,000 units at $6.95) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 187,171 units (SEC Form 4)